BridgeBio reports positive Phase 3 CALIBRATE trial results in ADH1
Question
BridgeBio reports positive Phase 3 CALIBRATE trial results in ADH1
Direct answer
Statistically significant Phase 3 primary endpoint achievement accelerates FDA regulatory approval and commercial drug revenue timelines. — bullish pressure on BBIO via commercial pipeline valuation and regulatory approval probability repricing.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-12
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “BridgeBio reports positive Phase 3 CALIBRATE trial results in ADH1”, revision 1, evidence through 2026-10-12. https://marketontology.com/catalysts/2026-10-12/bridgebio-reports-positive-phase-3-calibrate-trial-results-in-adh1-db22cd
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| BBIO | ▲Bull | 1–5 days | commercial pipeline valuation and regulatory approval probability repricing | 61 |
BridgeBio reports positive Phase 3 CALIBRATE trial results in ADH1
Statistically significant Phase 3 primary endpoint achievement accelerates FDA regulatory approval and commercial drug revenue timelines. — bullish pressure on BBIO via commercial pipeline valuation and regulatory approval probability repricing.
91% normal PTH levels achieved in Phase 3 CALIBRATE study vs 0% on standard care.
- Source91% normal PTH levels achieved in Phase 3 CALIBRATE study vs 0% on standard care.
- TransmissionStatistically significant Phase 3 primary endpoint achievement accelerates FDA regulatory approval and commercial drug revenue timelines.
- SummaryBridgeBio announced successful Phase 3 trial data for encaleret in ADH1. 91% of treated patients achieved normal PTH levels compared to zero on standard care.
- BBIODirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Fed officials or competing data may reframe the print
- BBIO closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- BBIO price vs. pre-event level
- BBIO volume vs. 20-day average
- 2Y/10Y Treasury yield direction
- DXY direction
- Fed funds futures repricing
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| BBIO | Bullishdisagreed | 65.75 2026-10-12 | -3.73% | Pending | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1 · press_release · 2026-10-11
Related catalysts
- 2026-10-12BridgeBio Reports Positive Phase 3 CALIBRATE Trial Results for EncaleretBBIO-3.73%
- 2026-10-12BridgeBio Reports Positive Phase 3 CALIBRATE Trial Data for EncaleretBBIO-3.73%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.